Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Yoshikazu Kuboi

Kenzo Muramoto

Masaki Goto

Yoshihito Eguchi

Jean-Christophe P Harmange

Mark Spyvee

Seiichi Kobayashi

Satoshi Yamamoto

Naoki Yoneda

Tomohiro Matsushima

Makoto Kotake

Yoshiyuki Kawakami

Kenichi Chiba

Hiroshi Shirota

Hong Du

Fabian Gusovsky

Yoshiharu Mizui

Isao Tanaka

John (Yuan) Wang

Hideki Sakurai

Masanori Fujita

Akifumi Kimura

Takatoshi Kawai

Yong-Chun Shen

Megumi Kawada

Toshio Imai

Roch Boivin

Yimin Jiang

Miyuki Nishimura

Xiang-Yi Li

Jesse Chow

Charles-André Lemelin

Hiroshi Obaishi

Ken-ichi Chiba

Ray Wood

Keiko Mizuno

John Wang

Atsushi Inoue

John (yuan) Wang

A therapeutic agent for an inflammatory disease comprising an antibody or a CX3CR1 antagonist that inhibits an interaction of fractalkine and CX3CR1 is provided.

Treating inflammatory diseases with antibodies that inhibit fractalkine-CXCR1 interaction

The present invention provides methods for the use of compounds having formula (I) in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R-R, t, X, Y, Z, and n are as defined herein.

Macrocyclic compounds useful as pharmaceuticals

The present invention provides compositions comprising compounds having formula (I): 

The present invention provides compounds having formula (I): 

There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there can be provided an antibody drug for suppressing chemotaxis and cytotoxic activity of killer lymphocytes by suppressing an interaction between CX3CR1 and fractalkine.

Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine

The present invention provides a compound which has cytokine production inhibitory activity and is useful for the treatment of diseases which is associated with cytokine. The compound is represented by the following general formula (I) [wherein A represents a cyclic group which may be substituted; the partial structure -DE- represents a group represented by &#x2014;CHCH&#x2014; or &#x2014;CH&#x2550;CH&#x2014;; W represents a group represented by &#x2014;CH&#x2014;, &#x2014;CHCH&#x2014;, &#x2014;CH&#x2550;CH&#x2014; or &#x2014;CH&#x2550;; the partial structure &#x3e;XY&#x2014; represents a group represented by &#x3e;CH&#x2014;(CH)&#x2014;, &#x3e;C&#x2550;CH&#x2014;, &#x3e;CH&#x2014;CH&#x2014;CH(OH)&#x2014;, &#x3e;CH&#x2014;CH&#x2014;C(&#x2550;O)&#x2014;, &#x3e;CH&#x2014;O&#x2014; or &#x3e;CH&#x2014;O&#x2014;CO&#x2014;, provided that when W is &#x2014;CH&#x2550;, then XY&#x2014; represents C&#x2014;(CH)&#x2014;; Z represents a divalent aliphatic hydrocarbon group; Rand R, which may be the same or different, each represents a hydrogen atom, or a hydroxyl, alkoxy or alkoxyalkoxy group; m is an integer of 0 or 1].

Cyclooctanone derivatives and cyclodecanone derivative, and use thereof

Growing community of inventors

Tsukuba, Japan

Yoshikazu Kuboi